This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

7 Stocks Soaring on Monster Volume

Idenix pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Idenix pharmaceuticals (IDIX) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the U.S. and Europe. This stock is trading up 16.2% at $10.89 in recent trading.

Today's Volume: 4.8 million

Average Volume: 1.5 million

Volume % Change: 565%

Shares of IDIX are skyrocketing higher today after the company reported positive mid-stage trial date for its hepatitis C drug, suggesting it was closer to competing with larger drugmakers. Data from the trial showed that nearly all patients who responded to Idenix's experimental treatment were able to sustain their defense against the virus.

>>22 Biopharma Stocks With Breakout Potential

From a technical perspective, IDIX is gapping up huge here with monster volume. This move has pushed IDIX into breakout territory since the stock has taken out some near-term overhead resistance at $10.40 to $10.43.

Traders should look for long-biased trades if this breakout holds, and if IDIX can trigger its next major breakout trade. That trade will hit once IDIX takes out some more overhead resistance at $11.92 to $12.68 with high volume. Look for a sustained move or close above those levels with volume that's near or above 1.5 million shares. If we get that action soon, then IDIX could easily re-test and possibly take out its 2012 high of $15.25.

On the flipside, I would avoid long-biased trades if IDIX fails to hold that breakout above $10.40 to $10.43.
5 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CHKP $82.01 -0.18%
CRZO $32.41 -1.16%
IDIX $24.50 0.20%
SODA $14.47 2.26%
TSLA $222.56 -4.20%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs